Utah Medical Products Inc. Announces Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2011
January 31, 2012 at 09:00 am
Share
Utah Medical Products Inc. announced earnings results for the fourth quarter and full year ended December 31, 2011. For the quarter, the company reported net sales of $9.91 million, operating income of $2.9 million, income before tax of $2.71 million, net income of $1.86 million or $0.509 earnings per share compared to net sales of $6.21 million, operating income of $2.18 million, income before tax of $2.23 million, net income of $1.21 million or $0.414 earnings per share for the same period last year.
For the full year, the company reported net sales of $37.86 million, operating income of $11.84 million, income before tax of $11.08 million, net income of $7.41 million or $2.034 earnings per share compared to net sales of $25.12 million, operating income of $8.92 million, income before tax of $9.04 million, net income of $6.01 million or $1.651 earnings per share for the same period last year. 2011 return on equity is 19%, prior to payment of dividends.
Utah Medical Products, Inc. is engaged in the business of producing medical services. The Company markets a range of medical devices used in critical care areas, especially the neonatal intensive care unit (NICU), the labor and delivery (L&D) department and the women's health center in hospitals, as well as medical devices sold to outpatient clinics and physician's offices. Its products include BT-CATH, CVX-RIPE, AROM-COT, MUC-X, CORDGUARD, DISPOSA-HOOD, DELTRAN PLUS, GESCO, PICC-NATE, LETZ System, Filshie Clip System, PATHFINDER PLUS, SUPRAPUBIC CATHETERIZATION, LIBERTY System, ENDOCURETTE, LUMIN, and BioPharm HP-PRT, among others. BT-CATH is a uterine balloon tamponade catheter for controlling severe postpartum hemorrhage. MUC-X is an aspiration device used immediately after birth to clear neonatal respiratory passages and reduce exposure to potential infections. AROM-CO is a finger cover with a prong designed to rupture maternal membranes with less patient pain and anxiety.